Home/Pipeline/Next-gen PI3K/mTOR inhibitors

Next-gen PI3K/mTOR inhibitors

Oncology

Pre-clinicalActive

Key Facts

Indication

Oncology

Phase

Pre-clinical

Status

Active

Company

Torqur

About Torqur

Torqur AG is a private, clinical-stage biotechnology company based in Zurich, Switzerland, developing targeted cancer therapies. Its core platform centers on creating a portfolio of disease-specific inhibitors of the PI3K/mTOR pathway, a key driver in many cancers. The lead asset, bimiralisib, is in Phase 2 development for actinic keratosis and other indications, with promising early clinical data. The company is a subsidiary of the Swiss Rockets incubator and is led by a board with deep expertise in oncology drug development and business.

View full company profile

Therapeutic Areas

Oncology Dermatology

Other Oncology Drugs

Drug	Company	Phase	Status
Bi-XDC with PROTACs	Coherent Biopharma	IND-enabling	Active
Bi-XDC with RPT	Coherent Biopharma	Early-stage	Active
mRNA Anticancer Vaccine	Sunshine Biopharma	Preclinical Research	Active
Biosimilar Bevacizumab	Organon (2)	Phase 3	Active
Biosimilar Pembrolizumab	Organon (2)	Phase 3	Active
BCL-2 Inhibitor Program	Vincerx Pharma	Preclinical	Research
Not specified in provided content	3Sbio	Various	Active
Preclinical Projects	Zion Pharma	Preclinical	Active
Attenukine Oncology Candidate	Teva	Phase 1	Active
XEMA Tumor Marker ELISA Kit	XEMA Group	Commercial	Active
KRAS inhibitor	Risen Pharma Tech	Preclinical/Phase 1	Active (AACR 2024 presentation)
KEAP1 Activator Program	Vividion Therapeutics	Phase 1	Active